2022 BIO International Convention News
Harnessing the power of chromatin science to target disease
June 29, 2022 -- ScienceBoard.net spoke with Martis Cowles, PhD, chief business officer at EpiCypher at the 2022 Biotechnology Innovation Organization International Convention about EpiCypher’s efforts to harness the power of chromatin science and provide insights into the chromatin regulatory system, which plays a critical role in many disease processes.
June 29, 2022 -- ScienceBoard.net spoke with Martis Cowles, PhD, chief business officer at EpiCypher at the 2022 Biotechnology Innovation Organization International Convention about EpiCypher’s efforts to harness the power of chromatin science and provide insights into the chromatin regulatory system, which plays a critical role in many disease processes.
Machine Bio seeks to fundamentally change how biotechs make protein
June 27, 2022 -- Protein purification is one of the biggest bottlenecks for biotechnology companies. However, startup Machine Bio is developing a next-generation protein synthesis platform that can produce pure protein from DNA in hours, minutes, or continuously using a single step process. Founders David Marash and Jack Fernandes spoke with ScienceBoard.net at the 2022 Biotechnology Innovation Organization International Convention.
June 27, 2022 -- Protein purification is one of the biggest bottlenecks for biotechnology companies. However, startup Machine Bio is developing a next-generation protein synthesis platform that can produce pure protein from DNA in hours, minutes, or continuously using a single step process. Founders David Marash and Jack Fernandes spoke with ScienceBoard.net at the 2022 Biotechnology Innovation Organization International Convention.
How one CDMO is navigating the global supply chain disruption
June 24, 2022 -- The COVID-19 pandemic has disrupted supply chains and production schedules around the world, forcing contract development and manufacturing organizations (CDMOs) to adapt. In a video interview at the 2022 Biotechnology Innovation Organization International Convention, Federico Pollano of Rentschler Biopharma discussed how the company is navigating the worldwide supply chain disruption.
June 24, 2022 -- The COVID-19 pandemic has disrupted supply chains and production schedules around the world, forcing contract development and manufacturing organizations (CDMOs) to adapt. In a video interview at the 2022 Biotechnology Innovation Organization International Convention, Federico Pollano of Rentschler Biopharma discussed how the company is navigating the worldwide supply chain disruption.
A case study on partnering between patient advocacy organizations and biotech
June 23, 2022 -- Last week's 2022 Biotechnology Innovation Organization (BIO) International Convention in San Diego gave patient advocacy organizations and biotech companies the first opportunity in three years to meet in person with the potential for partnering. However, it was a meeting at BIO 2019 between CMT Research Foundation and DTx Pharma that could serve as a model for such partnerships.
June 23, 2022 -- Last week's 2022 Biotechnology Innovation Organization (BIO) International Convention in San Diego gave patient advocacy organizations and biotech companies the first opportunity in three years to meet in person with the potential for partnering. However, it was a meeting at BIO 2019 between CMT Research Foundation and DTx Pharma that could serve as a model for such partnerships.
NIH seeks industry partners for technology transfer
June 23, 2022 -- The National Institutes of Health (NIH) is the world’s largest public funder of biomedical research. ScienceBoard.net spoke with Michael Salgaller of the National Cancer Institute at the 2022 Biotechnology Innovation Organization International Convention about NIH’s technology transfer professionals who work with its scientist inventors to find commercial partners to take their inventions to market.
June 23, 2022 -- The National Institutes of Health (NIH) is the world’s largest public funder of biomedical research. ScienceBoard.net spoke with Michael Salgaller of the National Cancer Institute at the 2022 Biotechnology Innovation Organization International Convention about NIH’s technology transfer professionals who work with its scientist inventors to find commercial partners to take their inventions to market.
Estonia’s ambitious plans to grow its biotech industry
June 22, 2022 -- The Baltic state of Estonia's biotech industry is expected to grow tenfold this decade and offers significant opportunities for Estonian companies. ScienceBoard.net spoke with Andres Sutt, Estonia’s minister of entrepreneurship and information technology, at the 2022 Biotechnology Innovation Organization International Convention in San Diego about the country’s ambitious plans to grow its biotech industry.
June 22, 2022 -- The Baltic state of Estonia's biotech industry is expected to grow tenfold this decade and offers significant opportunities for Estonian companies. ScienceBoard.net spoke with Andres Sutt, Estonia’s minister of entrepreneurship and information technology, at the 2022 Biotechnology Innovation Organization International Convention in San Diego about the country’s ambitious plans to grow its biotech industry.
Fauna Bio leverages animal genomics, hibernation biology to target human diseases
June 21, 2022 -- Biotech company Fauna Bio is leveraging animal genomics and hibernation biology to develop novel translational therapeutics for disease prevention and reduce the impact of age-related diseases in humans. ScienceBoard.net spoke with co-founder and CEO Ashley Zehnder about the intersection of animal genomics, hibernation biology, and human diseases.
June 21, 2022 -- Biotech company Fauna Bio is leveraging animal genomics and hibernation biology to develop novel translational therapeutics for disease prevention and reduce the impact of age-related diseases in humans. ScienceBoard.net spoke with co-founder and CEO Ashley Zehnder about the intersection of animal genomics, hibernation biology, and human diseases.
Using the power of plants to develop novel biopharmaceuticals
June 21, 2022 -- Biologics manufacturing company iBio is using plants as bioreactors to develop and manufacture therapeutics and vaccines. ScienceBoard.net spoke with CEO Tom Isett at the 2022 Biotechnology Innovation Organization International Convention about the company’s technology, programs, and more.
June 21, 2022 -- Biologics manufacturing company iBio is using plants as bioreactors to develop and manufacture therapeutics and vaccines. ScienceBoard.net spoke with CEO Tom Isett at the 2022 Biotechnology Innovation Organization International Convention about the company’s technology, programs, and more.
Apeiron Biologics' spinout invIOs targets solid tumors with novel cell therapy platform
June 20, 2022 -- Apeiron Biologics' spinout invIOs has a proprietary cell therapy platform for the modulation of intracellular immuno-oncology targets that enables rapid treatment of cancer patients using their own immune cells with short out-of-body time in out-patient settings. ScienceBoard.net spoke with invIOs’ CEO Peter Llewellyn-Davies at the 2022 Biotechnology Innovation Organization International Convention in San Diego.
June 20, 2022 -- Apeiron Biologics' spinout invIOs has a proprietary cell therapy platform for the modulation of intracellular immuno-oncology targets that enables rapid treatment of cancer patients using their own immune cells with short out-of-body time in out-patient settings. ScienceBoard.net spoke with invIOs’ CEO Peter Llewellyn-Davies at the 2022 Biotechnology Innovation Organization International Convention in San Diego.
Overcoming the challenges of off-the-shelf allogeneic cell therapies
June 20, 2022 -- Chimeric antigen receptor T-cell therapy has emerged as one of the major breakthroughs in cancer immunotherapy in the last decade. In a video interview at the 2022 Biotechnology Innovation Organization International Convention in San Diego, Dr. Jason Litten discussed the challenges that need to be overcome for allogeneic T cells to reach clinical success.
June 20, 2022 -- Chimeric antigen receptor T-cell therapy has emerged as one of the major breakthroughs in cancer immunotherapy in the last decade. In a video interview at the 2022 Biotechnology Innovation Organization International Convention in San Diego, Dr. Jason Litten discussed the challenges that need to be overcome for allogeneic T cells to reach clinical success.